United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Ticker
$UTHR
Sector
Primary listing
Employees
1,400
Headquarters
Website
UTHR Metrics
BasicAdvanced
$23bn
20.32
$27.07
0.59
-
Price and volume
Market cap
$23bn
Beta
0.59
52-week high
$609.35
52-week low
$272.12
Average daily volume
445k
Financial strength
Current ratio
4.794
Quick ratio
4.116
Interest coverage (TTM)
89.03%
Profitability
EBITDA (TTM)
1,548.5
Gross margin (TTM)
86.58%
Net profit margin (TTM)
40.61%
Operating margin (TTM)
46.06%
Effective tax rate (TTM)
19.97%
Revenue per employee (TTM)
$2,260,000
Management effectiveness
Return on assets (TTM)
12.62%
Return on equity (TTM)
20.26%
Valuation
Price to earnings (TTM)
20.316
Price to revenue (TTM)
7.624
Price to book
3.93
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
23.894
Free cash flow yield (TTM)
4.19%
Free cash flow per share (TTM)
23.013
Growth
Revenue change (TTM)
5.87%
Earnings per share change (TTM)
7.82%
3-year revenue growth (CAGR)
16.96%
10-year revenue growth (CAGR)
7.72%
3-year earnings per share growth (CAGR)
22.08%
10-year earnings per share growth (CAGR)
4.47%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
Jim Simons' fund bet early on Micron; Here's the fund's top stocks now
Finbold·1 week ago
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
Business Wire·3 weeks ago
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs